Regulatory Sep 01, 2026 · 1 min read · 90,087 views

Scholar Rock gets FDA nod for spinal muscular atrophy drug

Liam Turner

Editorial · Sep 01, 2026

FDA approves Scholar Rock's Isembyld (apitegromab) for SMA after Indiana manufacturing hurdles; shares jump 10% premarket

← Previous

Lack of biosimilar development could cost billions in lost savings, report warns

Novo's CEO knows the drugmaker needs to build confidence

Related Reading

Updated: Ultragenyx's new gene therapy will cost $3.95M

Sep 24, 2026

Roivant's road to a potential blockbuster begins with FDA approval for Lisraya

Sep 22, 2026

FDA faces questions on 'America First' provisions in latest user fee agreement

Sep 21, 2026